xRead - September 2022

Wise et al.

Page 234

1054. Krug N, Hohlfeld JM, Geldmacher H, et al. Effect of loteprednol etabonate nasal spray suspension on seasonal allergic rhinitis assessed by allergen challenge in an environmental exposure unit. Allergy. 2005;60:354–359. [PubMed: 15679722] 1055. Salapatek AM, Patel P, Gopalan G, Varghese ST. Mometasone furoate nasal spray provides early, continuing relief of nasal congestion and improves nasal patency in allergic patients. Am J Rhinol Allergy. 2010;24:433–438. [PubMed: 21067660] 1056. Zieglmayer P, Zieglmayer R, Bareille P, Rousell V, Salmon E, Horak F. Fluticasone furoate versus placebo in symptoms of grass-pollen allergic rhinitis induced by exposure in the Vienna Challenge Chamber. Curr Med Res Opin. 2008;24:1833–1840. [PubMed: 18498678] 1057. Bareille P, Murdoch RD, Denyer J, et al. The effects of a TRPV1 antagonist, SB-705498, in the treatment of seasonal allergic rhinitis. Int J Clin Pharmacol Ther. 2013;51:576–584. [PubMed: 23735181] 1058. Corren J, Wood RA, Patel D, et al. Effects of omalizumab on changes in pulmonary function induced by controlled cat room challenge. J Allergy Clin Immunol. 2011;127:398–405. [PubMed: 21281870] 1059. Horak F VTX-1463, a novel TLR8 agonist for the treatment of allergic rhinitis. Expert Opin Investig Drugs. 2011;20:981–986. 1060. Horak F, Zieglmayer P, Zieglmayer R, et al. The CRTH2 antagonist OC000459 reduces nasal and ocular symptoms in allergic subjects exposed to grass pollen, a randomised, placebo controlled, double-blind trial. Allergy. 2012;67:1572–1579. [PubMed: 23025511] 1061. Xiao JZ, Kondo S, Yanagisawa N, et al. Clinical efficacy of probiotic Bifidobacterium longum for the treatment of symptoms of Japanese cedar pollen allergy in subjects evaluated in an environmental exposure unit. Allergol Int. 2007;56:67–75. [PubMed: 17259812] 1062. Horak F, Zieglmayer P, Zieglmayer R, et al. Early onset of action of a 5-grass-pollen 300-IR sublingual immunotherapy tablet evaluated in an allergen challenge chamber. J Allergy Clin Immunol. 2009;124:471–477.e1. [PubMed: 19647862] 1063. Meyer W, Narkus A, Salapatek AM, Hafner D. Double-blind, placebo-controlled, dose-ranging study of new recombinant hypoallergenic Bet v 1 in an environmental exposure chamber. Allergy. 2013;68:724–731. [PubMed: 23621350] 1064. Nolte H, Maloney J, Nelson HS, et al. Onset and dose-related efficacy of house dust mite sublingual immunotherapy tablets in an environmental exposure chamber. J Allergy Clin Immunol. 2015;135:1494–1501.e6. [PubMed: 25636947] 1065. Patel D, Couroux P, Hickey P, et al. Fel d 1-derived peptide antigen desensitization shows a persistent treatment effect 1 year after the start of dosing: a randomized, placebo-controlled study. J Allergy Clin Immunol. 2013;131:103–109.e7. [PubMed: 22981787] 1066. Patel P, Holdich T, Fischer von Weikersthal-Drachenberg KJ, Huber B. Efficacy of a short course of specific immunotherapy in patients with allergic rhinoconjunctivitis to ragweed pollen. J Allergy Clin Immunol. 2014;133:121–129.e2. [PubMed: 23870670] 1067. Committee for Medicinal Products for Human Use (CHMP). Guideline on the clinical development of products for specific immunotherapy for the treatment of allergic diseases. Pre authorisation evaluation of medicines for human use. November 20, 2008. Doc. Ref. CHMP/EWP/18504/2006. European Medicines Agency; 2008:S1–S13. http:// www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/ WC500003605.pdf Accessed December 19, 2017. 1068. Department of Health U.S. and Human Services. U.S. Food and Drug Administration. Center for Drug Evaluation and Research (CDER). Guidance for Industry. Allergic rhinitis: clinical development programs for drug products. Draft: February 2016. Clinical/Medical Revision 1. https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ UCM071293.pdf. Accessed December 19, 2017. 1069. Agache I, Bilo M, Braunstahl GJ, et al. In vivo diagnosis of allergic diseases—allergen provocation tests. Allergy. 2015;70:355–365. [PubMed: 25640808] 1070. Riechelmann H, Epple B, Gropper G. Comparison of conjunctival and nasal provocation test in allergic rhinitis to house dust mite. Int Arch Allergy Immunol. 2003;130:51–59. [PubMed: 12576735]

Author Manuscript Author Manuscript Author Manuscript Author Manuscript

Int Forum Allergy Rhinol . Author manuscript; available in PMC 2020 June 10.